Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics.

Zhijuan ZHU; Jian CHEN; Mengxia YU; Feifei CHEN; Zhimei CHEN; Jiyu LOU; Hongyan TONG; Jian HUANG; Wenbin QIAN; Haitao MENG; Jie JIN

Return

Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics.

VernacularTitle:TET2基因在157例成人正常核型急性髓系白血病患者中的表达及其临床意义
Author: Zhijuan ZHU ¹ ; Jian CHEN ¹ ; Mengxia YU ¹ ; Feifei CHEN ¹ ; Zhimei CHEN ¹ ; Jiyu LOU ¹ ; Hongyan TONG ¹ ; Jian HUANG ¹ ; Wenbin QIAN ¹ ; Haitao MENG ¹ ; Jie JIN ¹
Author Information

1. Department of Hematology, The First Affiliated Hospital of Zhejiang University, Hangzhou 310003, China.
Publication Type:Journal Article
MeSH: Adult; Cytogenetic Analysis; Cytogenetics; DNA-Binding Proteins; genetics; Disease-Free Survival; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; genetics; Proto-Oncogene Proteins; genetics; Real-Time Polymerase Chain Reaction
From: Chinese Journal of Hematology 2014;35(9):802-807
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo explore the clinical significance of ten-eleven-translocation methylcytosine dioxygenase 2 (TET2) mRNA expression levels in adult acute myeloid leukemia patients with normal cytogenetics (CN-AML).
METHODSExpression levels of TET2 mRNA were measured by real-time PCR in 157 adult CN-AML, and its clinical impact in CN-AML was evaluated as well.
RESULTSTET2 gene expression levels from bone marrow mononuclear cells (BMMNCs) [7.29(3.41-9.99)] and CD34+ cells [6.02(5.64-6.54)] in CN-AML were significantly lower than those [BMMNCs: 8.13(6.68-9.04), P=0.026; CD34+ cells: 6.48(5.97-7.12), P=0.034] in healthy control. And TET2 mRNA level at diagnosis [7.32(6.11-8.41)] was obviously lower than that at complete remission [8.39(7.76-8.79), P<0.01]. CN-AML patients with lower levels of TET2 mRNA showed worse survival rate [(32.7±5.9)%] at 18-month than those with higher levels [(48.6±6.9)%, P=0.041]. In multivariate analysis, lower level of TET2 mRNA was an independent prognostic factor for OS [hazard ratio(HR)2.032, 95% confidence interval (CI)1.272-3.247, P=0.003] and event-free survival [HR 1.532, 95% CI 1.014-2.314, P=0.043].
CONCLUSIONThe level of TET2 mRNA is significantly lower in patients with CN-AML and it is an independent negative prognostic factor. TET2 could be an important factor for the molecular-based risk stratification in CN-AML.